GENE ONLINE|News &
Opinion
Blog

Flagship Pioneering Expands Horizons with Singapore Hub: A Gateway to Asia-Pacific Biotech Innovation

by Sinead Huang
Share To

On November 8, Flagship Pioneering, a bioplatform innovation company, announced a significant milestone with its expansion into the Asia-Pacific region. The move follows the establishment of a regional hub in Singapore, adding to the company’s international footprint, including its recent expansion in the UK. With a mission to foster a healthier and more sustainable future, Flagship Pioneering has been instrumental in originating and nurturing over 100 scientific ventures, amassing a total value exceeding $90 billion. The company’s ecosystem currently boasts 43 impactful entities spanning various sectors such as human therapeutics, agriculture, and nutrition.

Related article: Pfizer Partners with Renowned Life Sciences VC to Build Pipeline Projected to be Worth $7 Billion

Strategic Leadership in the Asia Pacific

To spearhead its presence in the APAC region, Flagship Pioneering has appointed André Andonian as the Chair of Asia Pacific and Senior Advisor. Andonian, with a wealth of experience advising global companies, particularly in the APAC region, brings his strategic insights to lead Flagship’s efforts in enhancing its global reach. He will play a pivotal role in guiding the company’s regional strategies, investor engagement, and institutional development, fostering collaborations between industry, academia, and healthcare systems.

Flagship’s decision to establish its hub in Singapore aligns with the city-state’s burgeoning biomedical ecosystem, fostering an environment conducive to transformative solutions and groundbreaking innovations. Jacqueline Poh, Managing Director of the Singapore Economic Development Board, emphasized the potential for collaboration in the growing region, emphasizing the positive impact on healthcare and sustainability. Singapore’s reputation as a thriving hub for innovation and research makes it an ideal location for Flagship’s foray into the Asia-Pacific market.

A Vision for Impactful Partnerships

The expansion of Flagship Pioneering in the APAC region signifies a strategic move towards strengthening collaborations with global leaders in industry, government, and academia. By tapping into the vibrant regional ecosystem, Flagship aims to amplify its impact on human health and the environment. André Andonian, in his role as Chair of Asia Pacific, expressed his excitement about building partnerships across Asia, facilitating Flagship and its bioplatform companies’ growth, ultimately aiming for maximum impact for patients and the planet.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
GeneOnline’s Weekly News Highlights: Oct 22-Oct 27
2023-10-31
LATEST
Breakthrough Stem Cell Treatment Shows Promise in Reversing Liver Disease
2023-12-08
2023 Taiwan Healthcare Expo: Showcasing Innovative Advances in Biomedical Technology
2023-12-07
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
EVENT
Scroll to Top